Orgenesis Inc (ORGS) 0.3800 $ORGS Orgenesis and
Post# of 273378
Posted On: 08/18/2016 1:10:17 PM
Orgenesis Inc (ORGS) 0.3800 $ORGS
Orgenesis and Atvio Biotech Launch Joint Venture for Gene and Cell Therapy Development Services
Marketwire Canada - Mon Aug 01, 8:01AM CDT
Dr. Ohad Karnieli Appointed CEO of Joint Venture
Orgenesis and CureCell Awarded Grant From the KORIL Fund for Diabetes Research and Development
Marketwire Canada - Tue Jun 07, 8:01AM CDT
GERMANTOWN, MD--(Marketwired - Jun 7, 2016) - Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a fully integrated cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that it and South Korean-based CureCell Co. Ltd. have been awarded a collaborative grant from the Korea-Israel Industrial R&D Foundation (KORIL-RDF) to finance their current co-development program. This program will include pre-clinical and clinical activities related to commercialization of the Orgenesis Autologous Insulin Producing (AIP) Cells for the treatment of diabetes.
Orgenesis and CureCell Create Joint Venture for Contract Development and Manufacturing of Cell Therapy Products in South Korea
Marketwire Canada - Wed Jun 01, 9:02AM CDT
GERMANTOWN, MD--(Marketwired - Jun 1, 2016) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, along with MaSTherCell SA, its wholly-owned, vertically integrated CDMO, specializing in cell therapy development for advanced medicinal products (the "Company"
, today announced that it has entered into a joint venture agreement with South Korean-based CureCell Co. Ltd. ("CureCell" . The joint venture will enable the two progressive organizations to collaborate in the contract development and manufacturing of cell therapy products in South Korea.
Orgenesis Approved for Additional European Grant for Further Development of its Type 1 Diabetes Program
Marketwired - Wed Apr 13, 9:42AM CDT
Orgenesis SPRL, a subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DGO6) for a budgeted EUR 1,303,636 support program for the development of a potential cure for Type 1 Diabetes. The financial support is awarded to Orgenesis as a recoverable advance payment at 55 percent of budgeted costs, or for a total of EUR 717,000.
Orgenesis CEO to Participate in BIO-Europe Spring 2016 Cell and Gene Therapy Interactive Panel Discussion
Marketwired - Fri Apr 01, 9:00AM CDT
Vered Caplan, CEO of Orgenesis Inc. (OTCQB: ORGS), will participate in an interactive panel discussion at BIO-Europe Spring 2016 in Stockholm, Sweden. Orgenesis is a fully-integrated biopharmaceutical company with a novel therapeutic technology for the treatment of diabetes and a fully owned subsidiary contract manufacturing and development company, MaSTherCell, which is devoted to cell therapy for advanced medicinal products.
Orgenesis Among the Top 10 Regenerative Medicine and Stem Cell Companies to Speak at BIT's 9th World Congress of Regenerative Medicine & Stem Cell-South Korea
Marketwired - Tue Mar 15, 5:38PM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, will offer valuable information at the 9th World Congress of Regenerative Medicine & Stem Cell-South Korea, with a focus on "The Next Big Thing in Biomedicine." The event, which will take place March 16-18, 2016, will provide attendees with information, resources and advice they may need to assist with research, strategic business planning, decision making and future professional developments.
Orgenesis Note Holders Elect to Convert $950,000 of Outstanding Notes
Marketwired - Tue Dec 29, 8:43AM CST
Orgenesis Inc. (OTCQB: ORGS) (the "Company" , a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that holders of $950,000 principal amount of the Company's convertible notes have agreed to convert the outstanding principal and accrued interest on the notes into units of Orgenesis securities comprised of shares of the Company's common stock at a per share conversion rate of $0.52 and three year warrants for an equal number of shares of common stock at a per share exercise price of $0.52. The conversion rate at which the note holders converted the notes is equivalent to the terms received by the equity investors in the Company's recently completed private placement, which was disclosed in the Company's Current report on Form 8-K filed with the Securities and Exchange Commission on December 16, 2015.
Orgenesis Secures $10 Million in Financing and Retains Ownership of MaSTherCell SA
Marketwired - Wed Dec 16, 8:01AM CST
Orgenesis Inc. (OTCQB: ORGS) (the "Company" , a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced the company has raised and fulfilled its obligation for a $10 million debt or equity financing and, per a prior agreement, allows Orgenesis to fulfill its obligation and finalize the acquisition of MaSTherCell, an advanced cell therapy and bio-manufacturing company. MaSTherCell will continue to function and be managed as a separate company.
Lyfebulb Connect Hosts Event in New York City With Orgenesis, With Focus on Working Toward a Practical Cure for Type 1 Diabetes
Marketwired - Mon Dec 07, 9:47AM CST
Lyfebulb, an organization dedicated to improving the quality of life for people living with chronic disease, and Orgenesis Inc. (OTCQB: ORGS), will co-host the December 8 Lyfebulb Connect event from 6 to 8 p.m. at Le Colonial NYC 149 East 57th Street, New York City. The event offers an opportunity for guests to connect and learn about emerging therapies for Type 1 Diabetes and the progression toward a practical cure.
Orgenesis CEO to Speak on Innovations in Diabetes Panel at IDEA Summit
Marketwired - Mon Nov 30, 1:06PM CST
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced its CEO, Vered Caplan, will participate in a panel discussion involving young companies spearheading cutting edge research on advancing Diabetes research.
Orgenesis and Biosequel Enter Collaboration Agreement for Conducting Clinical Trials for Type 1 Diabetes Treatment in Russia
Marketwired - Tue Nov 24, 9:54AM CST
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, announced that it has signed a collaboration agreement with Russian company, Biosequel LLC. The two companies will collaborate on conducting clinical trials in Russia. The collaboration will commence with the opening of the new Yauza Medical Center on Nov. 24, 2015.
Orgenesis to Deliver Presentation and Poster Session at World Congress of Regenerative Medicine & Stem Cell in Shanghai, China
Marketwired - Tue Nov 17, 10:19AM CST
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced it will deliver an oral presentation and a poster at the World Congress of Regenerative Medicine & Stem Cell in Shanghai, China from Nov. 18-20, 2015.
Orgenesis Delivers Poster Presentation at European Society of Gene and Cell Therapy (ESGCT) Congress
Marketwired - Fri Sep 18, 5:26PM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced it will present a poster session at the European Society of Gene and Cell Therapy (ESGCT) Congress held in Helsinki, Finland from September 17-20, 2015.
Orgenesis Featured in Special Report on Curing Diabetes
ACCESSWIRE - Wed Sep 09, 1:00AM CDT
NEW YORK, NY / ACCESSWIRE / September 9, 2015 / Orgenesis, Inc. (OTCQB:ORGS) and Scott Carmer the Company's U.S. CEO, is featured in the Special Report: Curing Diabetes. To view the segment please visit: https://www.youtube.com/watch?v=6JhXF0VIj50.
Farmers Embrace New Technology to Relieve Drought Pressure and Increase Fruit & Vegetable Quality/Quantity Using Less Water
GlobeNewswire - Thu Aug 13, 2:08AM CDT
via PRWEB - Xgenex LLC, a Ponte Vedra Beach Florida biotechnology business, has entered into a commercial agreement with microorganism innovation company AquaBella Organic Solutions, for the North American sales of AquaBella bio-enzyme water treatment and OMRI listed TerraBella organic sustainable soil corrective and root inoculant, that improve produce quality and increase yield in a variety of soils and climates while relieving drought pressure in hard-hit areas of North America.
Orgenesis Subsidiary MaSTherCell to Manufacture TxCell's Lead Product Ovasave for Multi-National Phase 2b Trial
Marketwired - Wed Jul 29, 10:22AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that its wholly owned subsidiary, MaSTherCell, a Contract Development and Manufacturing Organization (CDMO) has entered into a Memorandum of Understanding with France-based TxCell (Paris: TXCL) (Euronext Paris: FR0010127662 - TXCL), to manufacture clinical batches of Ovasave(R), TxCell's lead product. Ovasave is an antigen specific autologous T regulatory somatic cell therapy in development for the treatment of Inflammatory Bowel Disease. As part of the Memorandum of Understanding, MaSTherCell and TxCell also agreed to enter into discussions for the long-term clinical and commercial manufacturing by MaSTherCell of TxCell products.
Orgenesis and Atvio Biotech Launch Joint Venture for Gene and Cell Therapy Development Services
Marketwire Canada - Mon Aug 01, 8:01AM CDT
Dr. Ohad Karnieli Appointed CEO of Joint Venture
Orgenesis and CureCell Awarded Grant From the KORIL Fund for Diabetes Research and Development
Marketwire Canada - Tue Jun 07, 8:01AM CDT
GERMANTOWN, MD--(Marketwired - Jun 7, 2016) - Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a fully integrated cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that it and South Korean-based CureCell Co. Ltd. have been awarded a collaborative grant from the Korea-Israel Industrial R&D Foundation (KORIL-RDF) to finance their current co-development program. This program will include pre-clinical and clinical activities related to commercialization of the Orgenesis Autologous Insulin Producing (AIP) Cells for the treatment of diabetes.
Orgenesis and CureCell Create Joint Venture for Contract Development and Manufacturing of Cell Therapy Products in South Korea
Marketwire Canada - Wed Jun 01, 9:02AM CDT
GERMANTOWN, MD--(Marketwired - Jun 1, 2016) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, along with MaSTherCell SA, its wholly-owned, vertically integrated CDMO, specializing in cell therapy development for advanced medicinal products (the "Company"
, today announced that it has entered into a joint venture agreement with South Korean-based CureCell Co. Ltd. ("CureCell" . The joint venture will enable the two progressive organizations to collaborate in the contract development and manufacturing of cell therapy products in South Korea. Orgenesis Approved for Additional European Grant for Further Development of its Type 1 Diabetes Program
Marketwired - Wed Apr 13, 9:42AM CDT
Orgenesis SPRL, a subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DGO6) for a budgeted EUR 1,303,636 support program for the development of a potential cure for Type 1 Diabetes. The financial support is awarded to Orgenesis as a recoverable advance payment at 55 percent of budgeted costs, or for a total of EUR 717,000.
Orgenesis CEO to Participate in BIO-Europe Spring 2016 Cell and Gene Therapy Interactive Panel Discussion
Marketwired - Fri Apr 01, 9:00AM CDT
Vered Caplan, CEO of Orgenesis Inc. (OTCQB: ORGS), will participate in an interactive panel discussion at BIO-Europe Spring 2016 in Stockholm, Sweden. Orgenesis is a fully-integrated biopharmaceutical company with a novel therapeutic technology for the treatment of diabetes and a fully owned subsidiary contract manufacturing and development company, MaSTherCell, which is devoted to cell therapy for advanced medicinal products.
Orgenesis Among the Top 10 Regenerative Medicine and Stem Cell Companies to Speak at BIT's 9th World Congress of Regenerative Medicine & Stem Cell-South Korea
Marketwired - Tue Mar 15, 5:38PM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, will offer valuable information at the 9th World Congress of Regenerative Medicine & Stem Cell-South Korea, with a focus on "The Next Big Thing in Biomedicine." The event, which will take place March 16-18, 2016, will provide attendees with information, resources and advice they may need to assist with research, strategic business planning, decision making and future professional developments.
Orgenesis Note Holders Elect to Convert $950,000 of Outstanding Notes
Marketwired - Tue Dec 29, 8:43AM CST
Orgenesis Inc. (OTCQB: ORGS) (the "Company"
, a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that holders of $950,000 principal amount of the Company's convertible notes have agreed to convert the outstanding principal and accrued interest on the notes into units of Orgenesis securities comprised of shares of the Company's common stock at a per share conversion rate of $0.52 and three year warrants for an equal number of shares of common stock at a per share exercise price of $0.52. The conversion rate at which the note holders converted the notes is equivalent to the terms received by the equity investors in the Company's recently completed private placement, which was disclosed in the Company's Current report on Form 8-K filed with the Securities and Exchange Commission on December 16, 2015. Orgenesis Secures $10 Million in Financing and Retains Ownership of MaSTherCell SA
Marketwired - Wed Dec 16, 8:01AM CST
Orgenesis Inc. (OTCQB: ORGS) (the "Company"
, a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced the company has raised and fulfilled its obligation for a $10 million debt or equity financing and, per a prior agreement, allows Orgenesis to fulfill its obligation and finalize the acquisition of MaSTherCell, an advanced cell therapy and bio-manufacturing company. MaSTherCell will continue to function and be managed as a separate company. Lyfebulb Connect Hosts Event in New York City With Orgenesis, With Focus on Working Toward a Practical Cure for Type 1 Diabetes
Marketwired - Mon Dec 07, 9:47AM CST
Lyfebulb, an organization dedicated to improving the quality of life for people living with chronic disease, and Orgenesis Inc. (OTCQB: ORGS), will co-host the December 8 Lyfebulb Connect event from 6 to 8 p.m. at Le Colonial NYC 149 East 57th Street, New York City. The event offers an opportunity for guests to connect and learn about emerging therapies for Type 1 Diabetes and the progression toward a practical cure.
Orgenesis CEO to Speak on Innovations in Diabetes Panel at IDEA Summit
Marketwired - Mon Nov 30, 1:06PM CST
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced its CEO, Vered Caplan, will participate in a panel discussion involving young companies spearheading cutting edge research on advancing Diabetes research.
Orgenesis and Biosequel Enter Collaboration Agreement for Conducting Clinical Trials for Type 1 Diabetes Treatment in Russia
Marketwired - Tue Nov 24, 9:54AM CST
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, announced that it has signed a collaboration agreement with Russian company, Biosequel LLC. The two companies will collaborate on conducting clinical trials in Russia. The collaboration will commence with the opening of the new Yauza Medical Center on Nov. 24, 2015.
Orgenesis to Deliver Presentation and Poster Session at World Congress of Regenerative Medicine & Stem Cell in Shanghai, China
Marketwired - Tue Nov 17, 10:19AM CST
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced it will deliver an oral presentation and a poster at the World Congress of Regenerative Medicine & Stem Cell in Shanghai, China from Nov. 18-20, 2015.
Orgenesis Delivers Poster Presentation at European Society of Gene and Cell Therapy (ESGCT) Congress
Marketwired - Fri Sep 18, 5:26PM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced it will present a poster session at the European Society of Gene and Cell Therapy (ESGCT) Congress held in Helsinki, Finland from September 17-20, 2015.
Orgenesis Featured in Special Report on Curing Diabetes
ACCESSWIRE - Wed Sep 09, 1:00AM CDT
NEW YORK, NY / ACCESSWIRE / September 9, 2015 / Orgenesis, Inc. (OTCQB:ORGS) and Scott Carmer the Company's U.S. CEO, is featured in the Special Report: Curing Diabetes. To view the segment please visit: https://www.youtube.com/watch?v=6JhXF0VIj50.
Farmers Embrace New Technology to Relieve Drought Pressure and Increase Fruit & Vegetable Quality/Quantity Using Less Water
GlobeNewswire - Thu Aug 13, 2:08AM CDT
via PRWEB - Xgenex LLC, a Ponte Vedra Beach Florida biotechnology business, has entered into a commercial agreement with microorganism innovation company AquaBella Organic Solutions, for the North American sales of AquaBella bio-enzyme water treatment and OMRI listed TerraBella organic sustainable soil corrective and root inoculant, that improve produce quality and increase yield in a variety of soils and climates while relieving drought pressure in hard-hit areas of North America.
Orgenesis Subsidiary MaSTherCell to Manufacture TxCell's Lead Product Ovasave for Multi-National Phase 2b Trial
Marketwired - Wed Jul 29, 10:22AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that its wholly owned subsidiary, MaSTherCell, a Contract Development and Manufacturing Organization (CDMO) has entered into a Memorandum of Understanding with France-based TxCell (Paris: TXCL) (Euronext Paris: FR0010127662 - TXCL), to manufacture clinical batches of Ovasave(R), TxCell's lead product. Ovasave is an antigen specific autologous T regulatory somatic cell therapy in development for the treatment of Inflammatory Bowel Disease. As part of the Memorandum of Understanding, MaSTherCell and TxCell also agreed to enter into discussions for the long-term clinical and commercial manufacturing by MaSTherCell of TxCell products.
(0)
(0)